Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019
06 nov. 2019 16h02 HE
|
Ascendis Pharma A/S
– A single dose of TransCon TLR7/8 Agonist demonstrated sustained localized release of active drug over weeks and potent anti-tumor activity when administered directly into the tumor – ...